116 related articles for article (PubMed ID: 10501855)
1. Complement-mediated lysis of cultured osteosarcoma cell lines using chimeric mouse/human TP-1 IgG1 and IgG3 antibodies.
Olafsen T; Munthe Lund CK; Bruland OS; Sandlie I; Michaelsen TE
Cancer Immunol Immunother; 1999 Oct; 48(7):411-8. PubMed ID: 10501855
[TBL] [Abstract][Full Text] [Related]
2. Production and characterization of a set of mouse-human chimeric immunoglobulin G (IgG) subclass and IgA monoclonal antibodies with identical variable regions specific for Pseudomonas aeruginosa serogroup O6 lipopolysaccharide.
Preston MJ; Gerçeker AA; Reff ME; Pier GB
Infect Immun; 1998 Sep; 66(9):4137-42. PubMed ID: 9712759
[TBL] [Abstract][Full Text] [Related]
3. Characterization of a mouse/human chimeric monoclonal antibody (17-1A) to a colon cancer tumor-associated antigen.
Shaw DR; Khazaeli MB; Sun LK; Ghrayeb J; Daddona PE; McKinney S; LoBuglio AF
J Immunol; 1987 Jun; 138(12):4534-8. PubMed ID: 3584980
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxicity of antiosteosarcoma recombinant immunotoxins composed of TP-3 Fv fragments and a truncated Pseudomonas exotoxin A.
Onda M; Olafsen T; Tsutsumi Y; Bruland OS; Pastan I
J Immunother; 2001; 24(2):144-50. PubMed ID: 11265772
[TBL] [Abstract][Full Text] [Related]
5. Chimeric anti-ganglioside GM2 antibody with antitumor activity.
Nakamura K; Koike M; Shitara K; Kuwana Y; Kiuragi K; Igarashi S; Hasegawa M; Hanai N
Cancer Res; 1994 Mar; 54(6):1511-6. PubMed ID: 8137257
[TBL] [Abstract][Full Text] [Related]
6. Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59.
Ziller F; Macor P; Bulla R; Sblattero D; Marzari R; Tedesco F
Eur J Immunol; 2005 Jul; 35(7):2175-83. PubMed ID: 15971270
[TBL] [Abstract][Full Text] [Related]
7. Expression and functional activity of isotype and subclass switched human monoclonal antibody reactive with the base of the V3 loop of HIV-1 gp120.
Liu F; Bergami PL; Duval M; Kuhrt D; Posner M; Cavacini L
AIDS Res Hum Retroviruses; 2003 Jul; 19(7):597-607. PubMed ID: 12908937
[TBL] [Abstract][Full Text] [Related]
8. Antitumor immune effector mechanisms recruited by phage display-derived fully human IgG1 and IgA1 monoclonal antibodies.
Huls G; Heijnen IA; Cuomo E; van der Linden J; Boel E; van de Winkel JG; Logtenberg T
Cancer Res; 1999 Nov; 59(22):5778-84. PubMed ID: 10582699
[TBL] [Abstract][Full Text] [Related]
9. A bispecific monoclonal antibody directed against both the membrane-bound complement regulator CD55 and the renal tumor-associated antigen G250 enhances C3 deposition and tumor cell lysis by complement.
Blok VT; Daha MR; Tijsma O; Harris CL; Morgan BP; Fleuren GJ; Gorter A
J Immunol; 1998 Apr; 160(7):3437-43. PubMed ID: 9531304
[TBL] [Abstract][Full Text] [Related]
10. Antibody dependent cell-mediated cytotoxicity induced by chimeric mouse-human IgG subclasses and IgG3 antibodies with altered hinge region.
Michaelsen TE; Aase A; Norderhaug L; Sandlie I
Mol Immunol; 1992 Mar; 29(3):319-26. PubMed ID: 1557042
[TBL] [Abstract][Full Text] [Related]
11. Binding activities and antitumor properties of a new mouse/human chimeric antibody specific for GD2 ganglioside antigen.
Alvarez-Rueda N; Leprieur S; Clémenceau B; Supiot S; Sébille-Rivain V; Faivre-Chauvet A; Davodeau F; Paris F; Barbet J; Aubry J; Birklé S
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5613s-5620s. PubMed ID: 17875797
[TBL] [Abstract][Full Text] [Related]
12. Human IgG3 can adopt the disulfide bond pattern characteristic for IgG1 without resembling it in complement mediated cell lysis.
Brekke OH; Bremnes B; Sandin R; Aase A; Michaelsen TE; Sandlie I
Mol Immunol; 1993 Nov; 30(16):1419-25. PubMed ID: 8232327
[TBL] [Abstract][Full Text] [Related]
13. Preparation of human IgG and IgM monoclonal antibodies for MK-1/Ep-CAM by using human immunoglobulin gene-transferred mouse and gene cloning of their variable regions.
Kuroki M; Yamada H; Shibaguchi H; Hachimine K; Hirose Y; Kinugasa T; Ishida I; Kuroki M
Anticancer Res; 2005; 25(6A):3733-9. PubMed ID: 16302733
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies.
Brüggemann M; Williams GT; Bindon CI; Clark MR; Walker MR; Jefferis R; Waldmann H; Neuberger MS
J Exp Med; 1987 Nov; 166(5):1351-61. PubMed ID: 3500259
[TBL] [Abstract][Full Text] [Related]
15. Triggering Fc alpha-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy.
Stockmeyer B; Dechant M; van Egmond M; Tutt AL; Sundarapandiyan K; Graziano RF; Repp R; Kalden JR; Gramatzki M; Glennie MJ; van de Winkel JG; Valerius T
J Immunol; 2000 Nov; 165(10):5954-61. PubMed ID: 11067958
[TBL] [Abstract][Full Text] [Related]
16. Chimeric mouse human IgG3 antibodies with an IgG4-like hinge region induce complement-mediated lysis more efficiently than IgG3 with normal hinge.
Norderhaug L; Brekke OH; Bremnes B; Sandin R; Aase A; Michaelsen TE; Sandlie I
Eur J Immunol; 1991 Oct; 21(10):2379-84. PubMed ID: 1915551
[TBL] [Abstract][Full Text] [Related]
17. Improving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptors.
Gillies SD; Lan Y; Lo KM; Super M; Wesolowski J
Cancer Res; 1999 May; 59(9):2159-66. PubMed ID: 10232603
[TBL] [Abstract][Full Text] [Related]
18. Chimeric murine-human antibodies directed against folate binding receptor are efficient mediators of ovarian carcinoma cell killing.
Coney LR; Mezzanzanica D; Sanborn D; Casalini P; Colnaghi MI; Zurawski VR
Cancer Res; 1994 May; 54(9):2448-55. PubMed ID: 7512887
[TBL] [Abstract][Full Text] [Related]
19. Human IgG1, IgG3, and IgG3 Hinge-Truncated Mutants Show Different Protection Capabilities against Meningococci Depending on the Target Antigen and Epitope Specificity.
Giuntini S; Granoff DM; Beernink PT; Ihle O; Bratlie D; Michaelsen TE
Clin Vaccine Immunol; 2016 Aug; 23(8):698-706. PubMed ID: 27307451
[TBL] [Abstract][Full Text] [Related]
20. Chimerization of LL2, a rapidly internalizing antibody specific for B cell lymphoma.
Leung SO; Shevitz J; Pellegrini MC; Dion AS; Shih LB; Goldenberg DM; Hansen HJ
Hybridoma; 1994 Dec; 13(6):469-76. PubMed ID: 7737671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]